Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment Ganetespib
Drugstatus Investigational
Drugbank ID DB12047
Checkpoints NA
Signature Type Protein
Signature IFN-γ
Official Symbol IFNG
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Results indicated a significant increase in IFN-gamma producing cells following stimulation with gp100 peptide in the treatments groups, with the increase being the most dramatic in the combination treatment group, suggesting that thetreatment of ganetespib and anti-CTLA4 enhances antigen-specific CD8 T-cell generation.
PMID 28878208
Title HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes